PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-24.88%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while AGEN shows 0.00% growth. Joel Greenblatt would examine efficiency.
-27.70%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-27.70%
Both companies reducing total costs. Martin Whitman would check industry trends.
-8.45%
Interest expense reduction while AGEN shows 3.83% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
27.70%
EBITDA growth exceeding 1.5x AGEN's 6.21%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
27.70%
Operating income growth exceeding 1.5x AGEN's 5.55%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-27.70%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
117.18%
Similar tax expense growth to AGEN's 123.88%. Walter Schloss would investigate patterns.
-117.18%
Net income decline while AGEN shows 3.87% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-117.27%
EPS decline while AGEN shows 10.00% growth. Joel Greenblatt would examine position.
-117.27%
Diluted EPS decline while AGEN shows 10.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.